MWNA
STRO icon

Marshall Wace North America’s Sutro Biopharma STRO Stock Holding History

Marshall Wace North America’s Portfolio STRO Stock Details STRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-4,376
Closed -$814K – 1704
2021
Q2 		$814K Sell
4,376
-13,358
-75% -$2.61M ﹤0.01% 1071
2021
Q1 		$4.04M Sell
17,734
-18,065
-50% -$4.29M 0.02% 622
2020
Q4 		$7.77M Buy
+35,799
New +$5.93M 0.04% 431

Other funds holding STRO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SHI
SV Health Investors Boston, Massachusetts $32.3M AUM 20.15% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return

Marshall Wace North America's STRO Position: Q3 2021 in Review

Marshall Wace North America sold out of Sutro Biopharma (STRO) in Q3 2021, closing a stake of 4,376 shares — an estimated $814K sold.

Marshall Wace North America first reported a position in STRO in Q4 2020 and held it in 3 quarters. The position peaked at $7.77M in Q4 2020. 120 funds tracked by Wall St. Rank hold STRO as of Q3 2021.

  • Marshall Wace North America reported no remaining Sutro Biopharma position as of Q3 2021 after selling out during the quarter.
  • Marshall Wace North America sold 4,376 Sutro Biopharma shares in Q3 2021, an estimated $814K.
  • Marshall Wace North America first reported a position in Sutro Biopharma in Q4 2020 and held it in 3 quarters.
  • Marshall Wace North America's Sutro Biopharma position peaked at $7.77M in Q4 2020.
  • 120 funds tracked by Wall St. Rank held Sutro Biopharma as of Q3 2021.

Based on Marshall Wace North America's 13F filing for Q3 2021, filed 15 Nov 2021.